|4.91||-0.0400||-0.81%||Vol 1.06M||1Y Perf 26.60%|
|Sep 22nd, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||14.33||Analyst Rating||Hold 3.00|
|Potential %||-||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-100||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-/-100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-100||Income Ranking||— -|
|Price Range Ratio 52W %||87.07||Earnings Rating||—|
|Market Cap||123.37M||Earnings Date||8th Nov 2023|
Today's Price Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||8th Nov 2023|
|Estimated EPS Next Report||-0.61|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||520.82K|
|Avg. Monthly Volume||185.44K|
|Avg. Quarterly Volume||204.92K|
Decibel Therapeutics Inc. (NASDAQ: DBTX) stock closed at 4.91 per share at the end of the most recent trading day (a -0.81% change compared to the prior day closing price) with a volume of 1.06M shares and market capitalization of 123.37M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 37 people. Decibel Therapeutics Inc. CEO is Laurence E. Reid.
The one-year performance of Decibel Therapeutics Inc. stock is 26.6%, while year-to-date (YTD) performance is 139.51%. DBTX stock has a five-year performance of %. Its 52-week range is between 1.61 and 5.4, which gives DBTX stock a 52-week price range ratio of 87.07%
Decibel Therapeutics Inc. currently has a PE ratio of -1.10, a price-to-book (PB) ratio of 0.65, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -36.62%, a ROC of -43.55% and a ROE of -47.79%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Decibel Therapeutics Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.61 for the next earnings report. Decibel Therapeutics Inc.’s next earnings report date is 08th Nov 2023.
The consensus rating of Wall Street analysts for Decibel Therapeutics Inc. is Hold (3), with a target price of $14.33, which is 0.00% compared to the current price. The earnings rating for Decibel Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Decibel Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Decibel Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.25, ATR14 : 0.15, CCI20 : -132.56, Chaikin Money Flow : -0.41, MACD : 0.12, Money Flow Index : 41.61, ROC : -3.91, RSI : 51.68, STOCH (14,3) : 9.09, STOCH RSI : 0.00, UO : 38.64, Williams %R : -90.91), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Decibel Therapeutics Inc. in the last 12-months were:
Wed, 09 Aug 2023 19:03 GMT Decibel Therapeutics downgraded to Hold from Buy at JonesResearch- TipRanks. All rights reserved.
Wed, 09 Aug 2023 13:45 GMT H.C. Wainwright downgrades Decibel Therapeutics (DBTX) to a Hold- TipRanks. All rights reserved.
Wed, 09 Aug 2023 13:34 GMT Decibel Therapeutics downgraded to Neutral from Buy at H.C. Wainwright- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.